Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Triple-negative breast cancer (TNBC), locally recurrent unresectable or metastatic, in adult patients who have not received prior chemotherapy for metastatic disease and whose tumors express PD-L1 (CPS ? 10) as determined by a validated test (in combination with chemotherapy)
Last updated:
March 8, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Triple-negative breast cancer (TNBC), locally recurrent unresectable or metastatic, in adult patients who have not received prior chemotherapy for metastatic disease and whose tumors express PD-L1 (CPS ? 10) as determined by a validated test (in combination with chemotherapy)
Last updated:
March 8, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ? 1) as determined by a validated test, in combination with chemotherapy with or without bevacizumab, in adult patients
Last updated:
March 8, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ? 1) as determined by a validated test, in combination with chemotherapy with or without bevacizumab, in adult patients
Last updated:
March 8, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Stage IIB or IIC melanoma following complete resection, for adjuvant treatment of adult and pediatric (12 years and older) patients
Last updated:
March 8, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Stage IIB or IIC melanoma following complete resection, for adjuvant treatment of adult and pediatric (12 years and older) patients
Last updated:
March 8, 2023
Status:
Concluded with an LOI
Manufacturer:
Sanofi Genzyme Canada
Indication:
Multiple myeloma, relapsed or refractory, in patients who have received 1 to 3 prior lines of therapy (in combination with carfilzomib and dexamethasone)
Last updated:
March 7, 2023
Status:
Concluded with an LOI
Manufacturer:
Sanofi Genzyme Canada
Indication:
Multiple myeloma, relapsed and refractory, in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. (in combination with pomalidomide and dexamethasone)
Last updated:
March 7, 2023
Status:
Concluded with an LOI
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Severe Primary Insulin-like Growth Factor-1 Deficiency
Last updated:
February 6, 2023
Ledaga (chlormethine hydrochloride)
Status:
Concluded without agreement
Manufacturer:
Recordati Rare Diseases Canada Inc.
Indication:
Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL)
Last updated:
January 27, 2023